GeniPhys
ActiveGeniPhys is developing and commercializing its patented Collymer™ technology platform: a first-in-class polymerizable (scaffold-forming) collagen that supports custom design and fabrication of collagen materials for accelerated and improved tissue restoration and regeneration.
What it does
"GeniPhys is a groundbreaking lifetech and medtech company focused on developing and commercializing the innovative Collymer™ technology platform. Collymer™ is a unique polymerizable collagen protein designed for in situ scaffold formation, offering a novel approach to tissue restoration and regeneration. This proprietary biopolymer, free of cellular or immunogenic components, minimizes adverse reactions commonly associated with traditional collagen therapies. GeniPhys's biofabrication techniques allow for customizable formats, including self-assembling scaffolds, sheets, tubes, and gradient-density materials tailored for various applications. Preclinical studies have shown promising results in supporting cellularization, vascularization, and innervation, essential for regenerative healing in wound care, breast reconstruction, and vocal fold repair. With significant NSF SBIR funding and FDA 510(k) clearance for advanced wound management, GeniPhys is poised to revolutionize regenerative medicine across multiple fields."
Its site says now · captured 2026-08-23
GENIPHYS - NEW - Home
GeniPhys is developing and commercializing its patented Collymer ™ technology -a first-in-class polymerizable (scaffold-forming) collagen that supports custom design and fabrication of collagen...
Next to it in Healthcare and bio · regenerative medicine biomaterials
- BioLatticeSOSV SOSV IndieBio NY 08
Revolutionizing Tissue Repair
- AmplicorePlug and Play PnP 2025
Amplicore develops regenerative injectable therapeutics for musculoskeletal disorders, aiming to restore mobility and reduce pain.
- Omnispirant LimitedPlug and Play PnP 2025
OmniSpirant develops regenerative gene therapies with game changing innovation in respiratory medicine and oncology.
- Circadian OSSOSV SOSV IndieBio NY 2025 H2
Hacking the Circadian Operating System
- Grannus TherapeuticsPlug and Play PnP 2025
Grannus Therapeutics is a preclinical biotech startup, focused on developing novel first-in-class Hsp90𝛽-selective inhibitors for the treatment of multiple solid tumors.
- OsteoCure Therapeutics, IncPlug and Play PnP 2025
OsteoCure Therapeutics is advancing an adenosine platform with systemic treatments for reversing osteoporosis and local therapies for accelerating fracture and mitigating pain.
- Sift BiosciencesPlug and Play PnP 2025
Supercharging existing cancer therapies.
- Citrus OncologyTechstars TS 2026
Intelligent Specialty Care for Safer Cancer Treatment | Citrus Oncology